Loading
Brainomix
Brainomix Limited is a medical technology and digital health company based in Oxford, England. Founded in 2010 as a spin-out from the University of Oxford, Brainomix specializes in AI-powered imaging biomarkers and software solutions aimed at enhancing precision medicine. The company operates in over 30 countries and has its flagship platform deployed in more than 300 hospitals worldwide. Brainomix focuses on several key areas, including stroke care, lung fibrosis, and cancer imaging. Its flagship product, Brainomix 360 (e-Stroke), analyzes CT scans to provide real-time insights into brain damage, improving diagnosis and treatment times. The company also offers solutions for interstitial lung disease and cancer, utilizing advanced AI algorithms to support clinicians in making informed treatment decisions. With a commitment to improving patient outcomes, Brainomix integrates its technology seamlessly into existing healthcare workflows.
Funding
Every round, secondary, debt facility or acquisition involving Brainomix that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$6M